Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.
November 26, 2025 | Intelligent Commercialisation, artificial intelligence
Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.
As health and life sciences companies prepare for launch, teams often face the same challenge: data lives in silos. Omnichannel engagement data, field insights, and clinical indicators sit in separate systems – making it difficult to form a connected view of readiness or identify the levers that will most influence launch success.
InConcert™ unites these fragmented datasets to help commercial and medical leaders answer the questions that matter most:
- Which HCPs are showing early interest or unmet need?
- Where are we under- or over-investing across channels?
- How is our field and MSL activity likely to impact uptake?
- What indicators point to the strongest early launch opportunities?
By combining proprietary and client-owned data into one intelligent suite, InConcert™ transforms uncertainty into foresight – helping teams model scenarios, anticipate challenges, and activate strategies with clarity and confidence.
The full picture of commercial performance
InConcert™ integrates omnichannel, field, and clinical behavior data through an LLM-powered interface that enables intuitive, natural-language querying.
Guided by embedded data scientists and cross-functional experts from across Inizio, users can interrogate their data in real time – moving seamlessly from insight to action.
“InConcert™ helps clients bring their data into focus – turning scattered signals into a clear view of launch readiness,” said Mary-Kate McGarry, Chief Strategy & Innovation Officer, Inizio.
“When teams can see where physicians are most responsive, how field activity drives uptake, and where investment will have the greatest impact, they can make every launch decision with greater insight and confidence.”
A connected intelligence solution built for the pivotal pre-launch moment
At this stage of the lifecycle, success depends on understanding how behavior, communication, and clinical context intersect. InConcert™ combines four core data layers that, together, provide an unparalleled pre-launch vantage point:
- Omnichannel intelligence: More than 25M hours of HCP engagement data reveal where interest is building, which messages resonate, and which needs remain unmet.
- Field performance insight: Over 200 brand meeting analyses uncover how in-field activity shapes perception and influence, informing targeting and deployment strategy.
- Clinical foresight: U.S. and EU modeling of real-world evidence connects clinical signals to commercial outcomes – helping teams understand where market readiness is strongest.
- Predictive engagement: AI-driven models trained on longitudinal datasets forecast behavioral shifts, guiding investment toward the highest-impact channels and content.
Together, these layers create a continuously learning system – one that adapts to each therapy area and market, giving teams a real-time view of where and how to act.
Leading the future of Intelligent Commercialization™ with InConcert™
By uniting three critical assets, InConcert™ positions Inizio at the forefront of Intelligent Commercialization™.
- Proprietary data and infrastructure: Decades of integrated datasets spanning engagement, scientific, and commercial domains.
- A connective AI backbone: A modular, LLM-powered platform that makes complex data easy to query, interpret, and operationalize.
- Embedded expertise: Access to specialists from across Inizio – whose insights are both built into the models and available on demand – ensuring every interpretation is grounded in scientific and strategic rigor.
Fast to activate and easy to scale, InConcert™ can be deployed within 10–14 weeks, with flexible pilot options that integrate quickly into existing systems and launch workflows.
“Every InConcert™ deployment starts with a client challenge,” said Jamie Avallone, Chief Data Officer, Inizio Evoke.
“Whether it’s identifying high-value targets or validating go-to-market assumptions, InConcert™ gives teams the answers they need – turning complex data into clear, confident launch decisions.”
With more than 700 pharma and biotech partnerships, Inizio helps clients unlock the full potential of their data – transforming fragmented insights into the connected intelligence that drives confident, high-impact launches.
Learn more about InConcert™ or get in touch with one of our experts today.
This content was provided by Inizio
Company Details
Latest Content from Inizio
20 questions: Round 7
As it’s our 20th year anniversary, we invited our employees to play our version of 20 questions – this month “What project or event has been most memorable to you at RP?”Watch…
Innovation, sustainability and prosperity: Japan’s healthcare vision for the future
The vision for Japan 2035; A healthcare system that delivers unrivalled health outcomes, providing secure and responsive care for all members of society, sustainable, and contributing to prosperity in the…
Tools to action your segmentation
Our tools for ensuring a successful segmentation rollout
Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report
Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers in the US. The report will consist of 45-minute quantitative and 30-minute qualitative interviews with AD…
The value of design thinking: Incorporating creative and graphic design into pharma market research
How do we keep research design fresh and interesting? How do we ensure that we’re inspiring our respondents to give us enlightening new insights, and encourage new ways of thinking?There…
Research Partnership launches new patient Living with Psoriasis 2017 (EU) report
Living with Psoriasis is a study conducted amongst 615 patients in Europe. The report will consist of 30-minute online interviews with 600 patients and 15 qualitative interviews. It can be purchased…
Deep Dive – MINT: opportunities in ‘frontier’ markets?
According to British economist Jim O’Neill, MINT is the new BRIC. What is MINT? An acronym he coined for the ‘frontier’ markets of Mexico, Indonesia, Nigeria and Turkey. These are…
Webcast: Going for growth – Maximising your return on insights in Emerging Markets
Healthcare market research in emerging markets is still evolving, so finding the insights you require and then maximising the return on those insights can be challenging. Healthcare market research in emerging…
20 questions: Round 6
As it’s our 20th year anniversary, we invited our employees to play our version of 20 questions – this month we asked our employees about office life in Singapore.Watch the video: https://www.researchpartnership.com/news/2017/09/20-questions-round-6/
Ageing Asia: What does this mean for the future of healthcare?
Over the last 30 years, Asia’s economic growth has resulted in improved education and healthcare across a broad base of the population. This has contributed to declining fertility and increasing…